One real-world study on switching from a CGRP ligand mAb to erenumab in 22 patients reported neither the number of previous treatments, nor the number of absolute MHD/MMD at baseline and follow-up, nor the number of AMD (20). The gene discussed is CALCA; the disease is age-related macular degeneration.